|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 185,800.00 KRW | +1.98% |
|
+3.97% | +7.78% |
| 08-04 | Celltrion Files Phase 3 Trial Amendment for CT-P44 Biosimilar for Myeloma | MT |
| 07-24 | Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55 | MT |
Company Valuation: Celltrion, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 27,592,583 | 23,000,359 | 27,970,378 | 40,365,453 | 39,602,284 | 42,609,000 | - | - |
| Change | - | -16.64% | 21.61% | 44.32% | -1.89% | 7.59% | - | - |
| Enterprise Value (EV) 1 | 27,117 | 23,236 | 29,280 | 41,531 | 42,173 | 44,587 | 43,871 | 42,987 |
| Change | - | -14.31% | 26.01% | 41.84% | 1.55% | 5.72% | -1.6% | -2.02% |
| P/E | 47.2x | 41.6x | 53.7x | 91.7x | 38.8x | 28.3x | 24.4x | 21.6x |
| PBR | 6.87x | 5.34x | 2.46x | 2.2x | 2.32x | 2.3x | 2.12x | 1.94x |
| PEG | - | -9.54x | -20.3x | -2.1x | 0x | 0.6x | 1.5x | 1.7x |
| Capitalization / Revenue | 14.6x | 10.1x | 12.9x | 11.3x | 9.51x | 7.82x | 6.74x | 6.08x |
| EV / Revenue | 14.3x | 10.2x | 13.5x | 11.7x | 10.1x | 8.18x | 6.94x | 6.13x |
| EV / EBITDA | 27.9x | 26.6x | 32.6x | 45.6x | 29x | 20.6x | 17.3x | 15.2x |
| EV / EBIT | 36x | 35.9x | 44.9x | 84.4x | 36.1x | 24.5x | 20.1x | 17.2x |
| EV / FCF | 46x | -211x | 89.5x | 54.2x | 78.4x | 42.6x | 32.8x | 27.6x |
| FCF Yield | 2.17% | -0.47% | 1.12% | 1.85% | 1.28% | 2.35% | 3.05% | 3.62% |
| Dividend per Share 3 | 628.9 | - | 436.1 | 686.8 | 714.3 | 762.2 | 819.8 | 885.2 |
| Rate of return | 0.38% | - | 0.25% | 0.4% | 0.41% | 0.41% | 0.44% | 0.48% |
| EPS 3 | 3,515 | 3,362 | 3,273 | 1,873 | 4,438 | 6,572 | 7,617 | 8,610 |
| Distribution rate | 17.9% | - | 13.3% | 36.7% | 16.1% | 11.6% | 10.8% | 10.3% |
| Net sales 1 | 1,891 | 2,284 | 2,176 | 3,557 | 4,162 | 5,449 | 6,325 | 7,007 |
| EBITDA 1 | 972.1 | 873.6 | 897.2 | 910.3 | 1,456 | 2,169 | 2,534 | 2,821 |
| EBIT 1 | 753.9 | 647.2 | 651.5 | 492 | 1,168 | 1,820 | 2,188 | 2,499 |
| Net income 1 | 575.1 | 533.2 | 535.6 | 422.7 | 1,030 | 1,485 | 1,768 | 1,996 |
| Net Debt 1 | -475.5 | 235.5 | 1,310 | 1,165 | 2,571 | 1,978 | 1,262 | 378.2 |
| Reference price 3 | 166,042.75 | 139,979.07 | 175,736.96 | 171,703.30 | 172,380.95 | 185,800.00 | 185,800.00 | 185,800.00 |
| Nbr of stocks (in thousands) | 166,178 | 164,313 | 159,160 | 235,088 | 229,737 | 229,327 | - | - |
| Announcement Date | 2/16/22 | 3/3/23 | 2/29/24 | 2/25/25 | 2/4/26 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.72x | 8.03x | 20.18x | 0.42% | 29.19B | |
| 32.9x | 5.88x | 17.49x | 0.97% | 48.22B | |
| -22.77x | 340.62x | -20.81x | -.--% | 38.79B | |
| 29.98x | 3x | 12.95x | -.--% | 38.41B | |
| 46.6x | 4.72x | 30.74x | -.--% | 34.88B | |
| 32.6x | 5.33x | 24.22x | -.--% | 16B | |
| 22.53x | 1.98x | 8.57x | 1.17% | 13.53B | |
| 24.75x | 1.81x | 11.1x | -.--% | 12.22B | |
| 60.62x | 9.25x | 26.27x | 0.44% | 11.24B | |
| Average | 28.33x | 42.29x | 14.52x | 0.33% | 26.94B | |
| Weighted average by Cap. | 25.16x | 58.76x | 12.91x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- A068270 Stock
- Valuation Celltrion, Inc.
Select your edition
All financial news and data tailored to specific country editions
